Johnson & Johnson Enterprise Innovation Inc.

This study tests a new drug called NBTXR3 that is injected into tumors to make radiation therapy more effective. It is for adults aged 60 and older with advanced head and neck cancer who cannot receive standard chemotherapy. The trial will compare the combination of NBTXR3 plus r…

This early-stage study is testing an experimental drug called JNJ-86974680, alone or with another drug (cetrelimab) and radiation, in people with advanced non-small cell lung cancer. The main goal is to find safe and tolerable doses. About 126 participants will take part.

This early-stage study is testing an experimental chemotherapy drug, JNJ-1761981, that is injected directly into tumors. The goal is to find a safe and effective dose for people with advanced solid tumors who have not responded to standard treatments. The study will monitor side …

This early-phase study is testing whether a new drug called JNJ-90301900, injected directly into tumors, is safe and works when combined with standard chemotherapy and radiation for people with advanced head and neck cancer. About 30 participants with stage III or IV cancer will …

This early-phase study is testing a new treatment called JNJ-87704916, a virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors, either alone or combined with another drug (cetrelimab). The study aims to find the safest dose and check …

This study tests whether adding an experimental drug (JNJ-90301900) to standard chemoradiation and a follow-up immunotherapy (durvalumab) can shrink tumors more effectively in people with stage III non-small cell lung cancer that cannot be removed by surgery. About 130 adults wil…